The Open

The Long Desk

The Close · The Open · The Long Desk · Archive · Research
Wed, 19 Aug 2026
2000 companies · 2194 sector slots · 12 sectors · long-term lens

Trend Spotlight

Brent extends its Hormuz-driven rally to ~$93/bbl, a fourth straight up session, as India's own inflation print climbs toward the top of the RBI's comfort zone.

Brent traded up through Aug 19 to ~$92-93.6/bbl with the US-Iran standoff over the Strait of Hormuz still unresolved -- the price has extended above, not retraced below, the Aug 10 spike level that first flagged a durable risk premium. That matters beyond ENERGY: July CPI accelerated to 4.45% YoY, a 19-month high, with coverage explicitly tying the pickup to energy costs and rupee weakness (the rupee sits near 95.75/USD) -- a trend that runs somewhat counter to the RBI's own Aug 5 decision to lower its FY27 inflation forecast to 5.0%, and is worth watching for whether that forecast gets revised.

Day ahead

Overnight cues lean mildly risk-on into the Aug 20 open, tempered by still-elevated crude and bond volatility.

The S&P 500 snapped a three-session losing streak after the US Treasury said it would more than double repurchases of long-dated debt, easing a recent yield spike; Asian markets followed higher (Nikkei +1.36%, Kospi +5.89% -- an unusually large single-day move worth re-verifying before relying on it, ASX 200 +0.33%). GIFT Nifty traded around 24,219 on Aug 20, roughly flat-to-marginally-up from the prior close. New Fed Chair Kevin Warsh delivers his first Jackson Hole keynote on Aug 28, about three weeks ahead of the Sept 16 FOMC, after July's 9-3 vote was described as the least unified in years.

Arrived overnight

Fii/dii cash flows and the official index p/e published after The Close went out, and are included below. The evening report names what it is still waiting for, so nothing appears without having been declared missing first.

Reporting today

No tracked name reports today.

Coming up

Source: NSE event calendar, filtered to the 2000 tracked names.

Market Overview

IndexClosePoints ChangeP/EP/B
Nifty 50 24,078.30 ▼ -76.60 ▼ -0.32% 20.36 2.92
Nifty Next 50 73,900.65 ▼ -408.25 ▼ -0.55% 19.54 3.35
Nifty 500 23,386.20 ▼ -86.20 ▼ -0.37% 22.72 3.28
Nifty Bank 57,239.75 ▼ -22.65 ▼ -0.04% 13.54 1.71
NIFTY Midcap 100 63,408.75 ▼ -130.65 ▼ -0.21% 30.56 4.43
▲ 848 advancing ■ 27 unchanged ▼ 1749 declining of 2624 equities, vs the 2026-08-18 close
Cash market, ₹ crore
FII / FPI net
▲ +407.99
bought 12,876 · sold 12,468
DII net
▲ +3,973.72
bought 17,289 · sold 13,315

Source: NSE ind_close_all_20260819 (levels, index P/E and P/B) and the full-market bhavcopy (breadth).

Since We Flagged

The desk's track record — the FIRST call made on each standing name, against its call today. Entry price is the close on the day of that first call, read from the cached bhavcopy for that date. "Unchanged" means the original call still stands.

CompanyFirst flaggedVerdict then Verdict nowAt flagNow Move
Sapphire Foods India LtdSAPPHIRE Wed, 5 Aug 2026 AVOID unchanged ₹202.52 ₹233.71 ▲ +15.4%
Oriental Hotels LtdORIENTHOT Tue, 18 Aug 2026 BUY unchanged ₹121.21 ₹139.50 ▲ +15.1%
Excel Industries LtdEXCELINDUS Tue, 18 Aug 2026 HOLD unchanged ₹985.20 ₹1,133.25 ▲ +15.0%
Devyani International LtdDEVYANI Wed, 5 Aug 2026 AVOID unchanged ₹125.09 ₹142.90 ▲ +14.2%
Godrej Consumer Products LtdGODREJCP Wed, 5 Aug 2026 HOLD unchanged ₹1,069.00 ₹930.00 ▼ -13.0%
Bosch LtdBOSCHLTD Wed, 5 Aug 2026 QUALITY-WAIT unchanged ₹42,920.00 ₹48,460.00 ▲ +12.9%
Zaggle Prepaid Ocean Services LtdZAGGLE Tue, 18 Aug 2026 HOLD unchanged ₹165.88 ₹186.04 ▲ +12.2%
Gland Pharma LtdGLAND Wed, 5 Aug 2026 QUALITY-WAIT unchanged ₹2,545.10 ₹2,841.30 ▲ +11.6%
NLC India LtdNLCINDIA Wed, 5 Aug 2026 AVOID unchanged ₹303.30 ₹268.05 ▼ -11.6%
Sonam LtdSONAMLTD Tue, 18 Aug 2026 BUY unchanged ₹60.31 ₹67.19 ▲ +11.4%
GFL LtdGFLLIMITED Tue, 18 Aug 2026 HOLD unchanged ₹51.22 ₹56.76 ▲ +10.8%
Power Finance Corporation LtdPFC Wed, 5 Aug 2026 HOLD unchanged ₹418.00 ₹374.45 ▼ -10.4%

Source: data/state.json (call memory) × data/prices/<date>.json.

Top Stories

TCS's chairman succession is confirmed contested, not clean, as nationwide labor protests dispute the company's own layoff numbers Information Technology

Reporting now shows Chandrasekaran's Aug 12 decision not to seek reappointment followed a Feb 2026 board vote that failed to win unanimous support -- one director, widely identified as Noel Tata, withheld consent -- producing a six-month stalemate rather than a routine, planned handover; no successor has been named yet. Separately, CITU organized nationwide protests outside TCS offices in Chennai, Bengaluru, Pune and Hyderabad on Aug 19, with the Union of IT & ITES Employees alleging the ongoing workforce reduction could reach 30,000 roles against TCS's stated ~12,000 -- both the scale of Aug 19's protests and the competing headcount figure are new since the claim was last assessed.

TCS

DLF's Q1 pre-sales collapsed 94% YoY with zero new launches, leaving its reiterated FY27 target riding entirely on an unexecuted H2 pipeline Realty

DLF's Q1 FY27 pre-sales fell 94% YoY to Rs 657 crore with no housing launches during the quarter, yet management reiterated its Rs 20,000 crore FY27 pre-sales target, saying Rs 14,000-15,000 crore is expected from launches later this fiscal including the 'The Dahlias' project and a Goa launch (~10% of guidance). Management frames this as a timing issue, not a demand one, but the underlying shortfall is more severe than a generic soft quarter, and the back-half pipeline is now doing all the work.

DLF

Lupin quantifies its guided US trough on the Q1 FY27 call: quarterly US sales to fall toward $250-280M from $366M as generics erode Tolvaptan/Mirabegron pricing Pharmaceuticals

Lupin posted record Q1 FY27 revenue of Rs 8,217 crore (+33% YoY, its 16th straight quarter of growth) and reiterated FY27 guidance of high-single-digit revenue growth, but cut FY27 EBITDA margin guidance to ~25% from 29.7% and guided quarterly US sales down to $250-280M as Apotex, Teva and a possible fourth entrant compete away Tolvaptan/Mirabegron pricing from Q2. This is management itself putting numbers on a trough it had already flagged -- a bounded, quantified dip rather than new bad news, with recovery only expected from FY28.

LUPIN

Aurobindo Pharma subsidiary Eugia draws a USFDA Warning Letter after an OAI-classified inspection, company says impact is contained Pharmaceuticals

Eugia Pharma Specialities' Unit I (Telangana), a wholly-owned Aurobindo subsidiary, received a USFDA Warning Letter -- disclosed Aug 14 -- following Official Action Indicated status from a Feb 2026 inspection. The company says existing US supply is unaffected and the unit accounts for roughly 2% of group revenue, and states it will continue cooperating with the FDA. A confirmed regulatory action, but on the evidence available it reads as contained to one unit rather than a broader quality-system failure.

AUROPHARMA

RBI's NBFC revolving-credit draft stays in its comment window; Bajaj Finance's ~6% reaction is already several sessions old Financial Services

The RBI's Aug 6 draft, which would let only card-authorised NBFCs offer revolving credit, remains open for comment through Aug 28, with no final notification issued yet -- whether it lands unchanged is still untestable. Bajaj Finance shares already fell as much as 6% on the initial news, with one report putting the Bajaj group market-value hit at roughly Rs 55,000 crore (single-sourced, not cross-checked); nothing new moved this specific story today.

BAJFINANCE

Sector Scorecard

Entry score is 40% cheap-vs-history + 25% quality trend + 20% news catalyst + 15% technicals, for the 5 sectors with a researched catalyst. The other 7 show : no catalyst was researched for them, so their score renormalises over the remaining three inputs rather than assuming a neutral headline. ≥62 accumulate · 45–61 watch · <45 avoid.

SectorStanceEntryCheap QualityTechNews IndexIdx P/EB/W/H/A
Information Technology 10 scanned · 4 researched ACCUMULATE 63.9 60.0 93.2 46.4 -0 ▲ +0.73% 19.4 1/2/7/0
Banks 14 scanned · 2 researched AVOID 44.6 25.8 61.3 66.6 ▼ -0.04% 13.5 2/0/10/2
Pharmaceuticals 20 scanned · 7 researched AVOID 43.4 11.7 75.2 66.3 +0 ▼ -0.18% 40.7 3/8/8/1
Automobiles 15 scanned · 5 researched AVOID 39.6 7.0 76.0 65.8 ▼ -0.27% 33.9 4/4/5/2
FMCG 15 scanned · 3 researched ACCUMULATE 83.6 92.5 94.7 41.6 ▼ -0.55% 32.9 1/6/8/0
Metals & Mining 15 scanned · 3 researched AVOID 44.6 15.6 77.1 67.6 ▼ -0.02% 15.9 4/3/6/2
Realty 10 scanned · 2 researched WATCH 57.2 51.5 60.4 78.2 -0 ▼ -0.05% 38.0 1/1/4/4
Energy & Power 40 scanned · 1 researched WATCH 60.1 61.1 69.2 56.1 +0 ▼ -1.18% 14.8 8/4/14/14
Financial Services 20 scanned · 5 ranked elsewhere · 1 researched WATCH 56.2 70.8 36.1 59.5 +0 ▼ -0.36% 15.9 2/0/12/6
Healthcare & Hospitals 20 scanned · 16 ranked elsewhere · 7 researched AVOID 44.7 16.3 77.9 65.2 ▼ -0.31% 43.0 3/7/9/1
Hospitality & Tourism 15 scanned · 2 researched ACCUMULATE 62.8 58.5 71.3 60.2 ▲ +0.08% 90.4 4/3/4/4
Diversified & Other 2000 scanned · 173 ranked elsewhere · 31 researched WATCH 54.9 50.0 62.2 55.6 274/243/855/628

Source: data/verdicts.json × NSE sector index closes.

Stocks to Watch

New calls first, then the highest long-term composites. Each shows the figures that selected it — open the desk for the full six-lens panel.

new call this session
P/E in the 40th percentile of its own 3-year range · ROCE 19.3% (up 3.3pt over 5y) · Piotroski 7/9
Composite 76.0 P/E 18.1 ROCE 19.3% Piotroski 7/9
new call this session
P/E in the 59th percentile of its own 3-year range · ROCE 19.6% (up 2.6pt over 5y)
Composite 72.4 P/E 67.97 ROCE 19.6% Piotroski 5/9
new call this session
P/E in the 6th percentile of its own 3-year range · ROCE 6.52% (down 16.5pt over 5y) · -26.0% off its 52-week high
Composite 66.0 P/E 41.34 ROCE 6.52% Piotroski 5/9
new call this session
P/E in the 12th percentile of its own 3-year range · ROCE 13.3% (down 15.7pt over 5y) · -26.5% off its 52-week high
Composite 64.3 P/E 18.21 ROCE 13.3% Piotroski 3/9
new call this session
P/E in the 10th percentile of its own 3-year range
Composite 63.8 P/E 13.04 ROCE 5.76% Piotroski 5/7
new call this session
P/E in the 1th percentile of its own 3-year range · ROCE 15.0% (down 7.0pt over 5y) · -35.7% off its 52-week high
Composite 61.0 P/E 35.06 ROCE 15.0% Piotroski 4/9

How We Evaluate

MetricWhy it is in the frameworkSource
Return on capital, level and trendDurable high ROCE predicts future returns; the trend separates a moat from a good year Novy-Marx 2013 JFE
Gross profitability (GP/assets)As predictive as book-to-market, and less prone to the value trap Novy-Marx 2013 JFE
Piotroski F-scoreA nine-signal accounting checklist that separates real improvers from statistically cheap traps Piotroski 2000 JAR
Cash-flow-to-net-profitAccrual-heavy profit reverts; cash-backed profit persists Sloan 1996 TAR
P/E versus the stock's own historyCheap relative to itself, not to a peer set that may be expensive as a whole Basu 1977 JF
Book-to-marketThe value premium, in its original form Fama–French 1992 JF
EV/EBITDACapital-structure-neutral, so it compares a leveraged firm to an unleveraged one Practitioner standard
Altman Z and interest coverageDistressed firms have delivered lower, not higher, returns — screen them out rather than chase them Altman 1968 JF; Campbell/Hilscher/Szilagyi 2008 JF
52-week-high proximity, 200-DMANearness to the high has predicted continuation — but momentum crashes, so never alone George & Hwang 2004 JF; Daniel & Moskowitz 2016 JFE
Promoter pledgePledged promoter holding is a governance red flag ahead of a forced sale Not currently available from either source — no penalty is applied

Full derivation in METHODOLOGY.md.